Phaseline

Companies › Beijing Pearl Biotechnology Limited Liability Company

Beijing Pearl Biotechnology Limited Liability Company: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PLB1001 (Vebreltinib)
MET inhibitor
METPhase 3Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer; GlioblastomaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06105619PLB1001 (Vebreltinib)Phase 2GlioblastomaOncologyDec 2026
NCT05989542PLB1001 (Vebreltinib)Phase 3Non-small Cell Lung CancerOncologySep 2027
NCT06930794PLB1001 (Vebreltinib)Phase 3Non-Small Cell Lung CancerOncologyFeb 2029

Targets

MET (1)

Companies with the same targets

AstraZeneca Johnson & Johnson (Janssen) Exelixis AbbVie Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Chia Tai Tianqing Pharmaceutical Group Beijing Scitech-Mq Pharmaceuticals IDEAYA Biosciences Shanghai Henlius Biotech DeuterOncology

Companies built like this

Apollomics Abion LaNova Medicines Zhejiang Quetzal Therapeutics Quercis Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.